GNRO — Geneuro SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: GeNeuro Completes Patient Enrollment In Phase 2A Study Of GNbAC1 In Type 1 Diabetes
Brief: Geneuro To Receive 12 Million Euros Milestone Payment From Servier In Phase 2B Study
Brief: GeNeuro cash and cash equivalents totalled 16.4 million euros at 30 September
Brief: Geneuro H1 net loss widens to 8.0 millon euros
Brief: Geneuro publishes data supporting role of retroviral pathogenic envelope protein in type 1 diabetes
Brief: Geneuro and Servier announce 6-month results from CHANGE-MS Phase 2b study in multiple sclerosis
Brief: Geneuro Q2 operating revenues down at 1.5 million euros
Brief: Geneuro announces first patient treated in phase 2A study with GNBAC1 in type 1 diabetes
Brief: Geneuro Q1 operating revenue 1.6 million euros, up 64 pct
Brief: Geneuro FY operating revenues rise to 5.9 million euros
Brief: Geneuro initiates Phase 2a study with GNbAC1 in type 1 diabetes in Australia
U.S. approves Roche drug that targets severe form of MS (updated)
Brief: Geneuro signs agreement with NIH to develop antibody treatment for ALS
Brief: Geneuro FY revenues up at 6.4 million euros
Brief: GeNeuro provides update on GNbAC1 multiple sclerosis clinical program
Brief: Geneuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis
Brief: Geneuro Q3 revenue up at 1.2 million euros
Brief: Geneuro H1 net loss widens to 6.8 million euros
Brief: GeNeuro Phase 2b Multiple Sclerosis study recruitment reaches halfway mark ahead of schedule